Literature DB >> 6638688

Unresponsiveness of Legionella bozemanii pneumonia to erythromycin administration despite in vitro sensitivity.

M M Parker, A M Macher, J H Shelhamer, J E Balow, V Gill, J E Parrillo.   

Abstract

We report a case of Legionella bozemanii pneumonia that failed to respond clinically and microbiologically to erythromycin administration. The organism was recovered from bronchial brushings and washings and was demonstrated to be sensitive in vitro to erythromycin as well as to rifampin and sulfamethoxazole-trimethoprim. The patient received a 9-day course of erythromycin before she died. Nonetheless, postmortem lung tissue yielded Legionella bozemanii. In treating Legionella pneumonia unresponsive to erythromycin, addition of another antibiotic, based on sensitivity testing, should be considered.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6638688     DOI: 10.1164/arrd.1983.128.5.955

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  5 in total

Review 1.  Current and emerging Legionella diagnostics for laboratory and outbreak investigations.

Authors:  Jeffrey W Mercante; Jonas M Winchell
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

Review 2.  Legionnaires disease: historical perspective.

Authors:  W C Winn
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

3.  Inhibitory and bactericidal activities of levofloxacin, ofloxacin, erythromycin, and rifampin used singly and in combination against Legionella pneumophila.

Authors:  A L Baltch; R P Smith; W Ritz
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

4.  Inhibition of Legionella pneumophila multiplication within human macrophages by antimicrobial agents.

Authors:  J L Vildé; E Dournon; P Rajagopalan
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

Review 5.  Legionnaires' disease: clinical differentiation from typical and other atypical pneumonias.

Authors:  Burke A Cunha
Journal:  Infect Dis Clin North Am       Date:  2010-03       Impact factor: 5.982

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.